Conferences EASL 2009
Other Infections
EASL 2009: Antiviral Agents with Activity against Both HIV and Hepatitis C Virus
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 02 June 2009 13:47
- Written by Liz Highleyman
Standard therapy for chronic hepatitis C virus (HCV) infection consists of pegylated interferon plus ribavirin, but several novel agents under study directly target various steps of the HCV lifecycle, an approach known as "STAT-C." Some of these investigational agents work similarly to certain antiretroviral drugs for HIV, suggesting it may be possible to develop drugs that have activity against both HIV-HCV, a potential benefit for HIV-HCV coinfected patients.
EASL 2009: Does HBV Viral Load Level Predict Development of Liver Fibrosis?
- Details
- Category: HBV Disease Progression
- Published on Friday, 29 May 2009 13:47
- Written by Liz Highleyman
Two studies presented at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL 2009) last month in Copenhagen looked at the association between HBV DNA level and development of fibrosis, with findings suggesting that the role of HBV viral load differs for hepatitis B "e" antigen (HBeAg) negative and HBeAg positive individuals.
Researchers Present Data on Investigational Cyclophilin Inhibitors Debio 025 and SCY-635
- Details
- Category: HCV Treatment
- Published on Friday, 15 May 2009 13:47
- Written by Liz Highleyman
At the 44th Annual Meeting of the European Association for the Study of the Liver (EASL 2009) last month in Copenhagen, researchers presented promising data from studies of a new class of agents for HCV therapy, cyclophilin inhibitors.
Acute Hepatitis C Affects Neurocognitive Functioning in People with HIV
- Details
- Category: Neurocognitive Problems
- Published on Friday, 22 May 2009 13:47
- Written by Liz Highleyman
Acute coinfection with hepatitis C virus (HCV) can contribute to neurocognitive impairment in people with HIV, according to a British study presented at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL 2009) last month in Copenhagen.
Investigational 2-Dose Dynavax Heplisav Hepatitis B Vaccine May Work Better than Standard 3-Dose Energix-B Vaccine
- Details
- Category: Experimental HBV Drugs
- Published on Tuesday, 12 May 2009 13:47
- Written by HIVandHepatitis.com
An investigational hepatitis B virus (HBV) vaccine may offer the same degree of protection with 2 doses as the standard Engerix-B vaccine does with 3 doses, according to a study presented at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL 2009) last month in Copenhagen.
Researchers Report Promising Results from Studies of 3 Therapeutic HCV Vaccines
- Details
- Category: HCV Vaccines
- Published on Tuesday, 19 May 2009 13:47
- Written by Liz Highleyman
Current standard therapy for chronic hepatitis C virus (HCV) infection consists of pegylated interferon plus ribavirin, and several directly targeted oral anti-HCV agents are in advanced stages of development. But another approach -- therapeutic vaccines -- is also under study, as reported in 3 presentations at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL 2009) last month in Copenhagen.
EASL 2009: Early Treatment of Acute Hepatitis C with Pegylated Interferon Monotherapy Produces Better Results than Delayed Combination Therapy
- Details
- Category: Acute Hepatitis C
- Published on Tuesday, 05 May 2009 13:47
- Written by Liz Highleyman
In a late-breaker presentation at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL 2009) last month in Copenhagen, K. Deterding and colleagues with the HEP-NET Acute HCV Study Group described findings from a randomized trial of early versus delayed treatment of acute hepatitis C.
Active Injection Drug Users and Those on Opiate Substitution Treatment Can Have Good Hepatitis C Therapy Outcomes
- Details
- Category: HCV Treatment
- Published on Monday, 18 May 2009 18:19
- Written by Liz Highleyman
Active injection drug users (IDUs) and those receiving opiate substitution can be successfully treated for chronic hepatitis C virus (HCV) infection, according to a French study presented at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL 2009) last month in Copenhagen.
Addition of Emtricitabine (Emtriva) Does Not Improve Response to Tenofovir (Viread) for Chronic Hepatitis B
- Details
- Category: HBV Treatment
- Published on Tuesday, 05 May 2009 13:47
- Written by Liz Highleyman
As described in a poster presented at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL 2009) last month in Copenhagen, T. Berg and an international team of colleagues conducted Study 106, comparing the efficacy of tenofovir/emtricitabine combination therapy versus tenofovir alone for the treatment of chronic hepatitis B.
Web Design and Development by